Minimal residual disease (MRD) assessment by flow cytometry after ASCT for AL amyloidosis: are we there yet?

    loading  Checking for direct PDF access through Ovid

Abstract

Abstract unavailable for this article.

Related Topics

    loading  Loading Related Articles